Skip to main content

Autosomal Dominant Polycystic Kidney Disease clinical trials at University of California Health

3 in progress, 2 open to eligible people

Showing trials for
  • A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

    open to eligible people ages 12-70

    This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Approximately 850 patients will be enrolled.

    at UCLA UCSF

  • An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

    open to eligible people ages 12 years and up

    This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with bardoxolone methyl. Patients will remain in the study until bardoxolone methyl is available through commercial channels or until patient withdrawal, whichever is sooner.

    at UCLA UCSF

  • Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

    Sorry, in progress, not accepting new patients

    This is a Phase 3, open-label, repeat-dose study designed to assess liver safety, non-liver safety, and efficacy in subjects who previously experienced liver chemistry test abnormalities while treated with tolvaptan and were permanently discontinued from the drug for that reason. Up to 50 eligible subjects will be enrolled and treated with lixivaptan for 52 weeks following titration to an optimal dose.

    at UCLA

Our lead scientists for Autosomal Dominant Polycystic Kidney Disease research studies include .

Last updated: